Remission of Acute Food Protein-Induced Enterocolitis Syndrome Confirmed by Oral Food Challenges in Japan.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
07 Oct 2022
Historique:
received: 08 09 2022
revised: 30 09 2022
accepted: 04 10 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 18 10 2022
Statut: epublish

Résumé

The oral food challenge test (OFC) is the gold standard for evaluating the remission of food protein-induced enterocolitis syndrome (FPIES). Few acute FPIES remissions confirmed by OFC were reported. This study aimed to examine the OFC for Japanese children with acute FPIES to evaluate its remission. A retrospective cohort study was performed on children with acute FPIES with remission evaluation by OFC based on one food challenge dose (1/50, 1/10, 1/2, and full dose per day). Acute FPIES remission was observed in 65.2% of patients (15/23 patients). Vomiting episodes occurred with 1/50 full doses on the first day among 75% of positive patients. The median duration between the onset and OFC was 14 months (IQR, 8-24 months). Soy was the most common causative food, followed by egg yolk, milk, and wheat. All patients could receive OFC safely without intensive care unit care, based on the FPIES OFC protocol. The remission rate of acute FPIES was high. However, vomiting episodes commonly occurred with 1/50 full doses on the first day. This study suggested that our OFC protocol for acute FPIES was safe and feasible, but it might be safer for some patients to start at a minimal loading dose.

Identifiants

pubmed: 36235810
pii: nu14194158
doi: 10.3390/nu14194158
pmc: PMC9570973
pii:
doi:

Substances chimiques

Allergens 0
Dietary Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Center For Child Health and Development
ID : 2022E-1

Références

Int Arch Allergy Immunol. 2019;180(2):113-119
pubmed: 31390649
J Allergy Clin Immunol. 2011 Mar;127(3):647-53.e1-3
pubmed: 21377033
Pediatr Allergy Immunol. 2017 Feb;28(1):6-17
pubmed: 27637372
World Allergy Organ J. 2020 Nov 07;13(11):100479
pubmed: 33204389
Clin Rev Allergy Immunol. 2019 Oct;57(2):261-271
pubmed: 30734159
Ann Allergy Asthma Immunol. 2021 May;126(5):489-497
pubmed: 33444729
J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):232-236
pubmed: 30320669
Clin Exp Allergy. 2012 Aug;42(8):1257-65
pubmed: 22805473
J Allergy Clin Immunol. 2017 Apr;139(4):1111-1126.e4
pubmed: 28167094
World Allergy Organ J. 2018 Feb 7;11(1):4
pubmed: 29441147
J Allergy Clin Immunol. 2017 Nov;140(5):1323-1330
pubmed: 28427879
Allergol Int. 2019 Jan;68(1):110-111
pubmed: 29759658
Allergy Asthma Clin Immunol. 2022 Jan 31;18(1):8
pubmed: 35101093
J Allergy Clin Immunol Pract. 2020 May;8(5):1702-1709
pubmed: 32004746
J Allergy Clin Immunol Pract. 2021 Jan;9(1):547-549.e1
pubmed: 33065366
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Allergol Immunopathol (Madr). 2005 Nov-Dec;33(6):312-6
pubmed: 16371218
Ann Allergy Asthma Immunol. 2021 May;126(5):469-477
pubmed: 33607250
Pediatr Allergy Immunol. 2022 Jan;33(1):e13649
pubmed: 34379825
J Allergy Clin Immunol Pract. 2022 Apr;10(4):1110-1112.e2
pubmed: 34800705

Auteurs

Koji Nishimura (K)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Kiwako Yamamoto-Hanada (K)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Miori Sato (M)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Kenji Toyokuni (K)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Hiroya Ogita (H)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Tomoyuki Kiguchi (T)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Yoshitsune Miyagi (Y)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Yusuke Inuzuka (Y)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Mayako Saito-Abe (M)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Makoto Irahara (M)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Fumi Ishikawa (F)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Shigenori Kabashima (S)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Yumiko Miyaji (Y)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Tatsuki Fukuie (T)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Ichiro Nomura (I)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Yukihiro Ohya (Y)

Allergy Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH